VeriChip Corporation Completes $8 Million Debt Financing
04 3월 2008 - 10:30PM
Business Wire
VeriChip Corporation (�VeriChip� or the �Company�) (NASDAQ:CHIP), a
provider of radio frequency identification (RFID) systems for
healthcare and patient-related needs, announced today it has
entered into an $8 million debt financing with Valens Offshore II,
Corp. (�Valens�). The financing is a thirteen-month,
non-convertible term loan bearing interest at an annual rate equal
to 12%. In consideration of the financing, VeriChip issued to
Valens 120,000 shares of the Company's common stock. The Company
will use $5.3 million of the proceeds from this financing to prepay
debt owed to Digital Angel (NASDAQ:DIGA). As a result of this
prepayment, the Company will not be obligated to make any further
debt service payments to Digital Angel until September 2009. By
eliminating all 2008 debt service payments, the financing will
result in an increase of more than $3.6 million to working capital
for the Company in 2008. Scott R. Silverman, Chairman and Chief
Executive Officer of VeriChip, said, �This new financing not only
enables us to eliminate more than $5 million in debt owed to
Digital Angel, but also provides us sufficient working capital to
fund our business plan, which includes a new consumer marketing
initiative, through early 2009.� About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida,
develops, markets and sells RFID systems used to identify, locate
and protect people and assets. VeriChip's goal is to become the
leading provider of RFID systems for people in the healthcare
industry. The Company recently began marketing its VeriMed� Patient
Identification System for rapidly and accurately identifying people
who arrive in an emergency room and are unable to communicate. This
system uses the first human-implantable passive RFID microchip, the
implantable VeriChip�, cleared for medical use in October 2004 by
the United States Food and Drug Administration. For more
information on VeriChip, please call 1-800-970-2447, or email
info@verichipcorp.com. Additional information can be found online
at www.verichipcorp.com. This press release contains certain
�forward-looking� statements (as such term is defined in the
Private Securities Litigation Reform Act of 1995). Forward-looking
statements included in this press release include, without
limitation, those concerning expectations for the Company�s ability
to fund its business plan. These forward-looking statements are
based on the Company�s current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions. Among
the important factors that could actual results to differ
materially from those expressed in, or implied by, the
forward-looking statements are our ability to successfully
implement our business strategy; our expectation that we will incur
losses, on a consolidated basis, for the foreseeable future; the
relative maturity in the United States and limited size of the
markets for our infant protection and wander prevention systems and
vibration monitoring instruments; the degree of success we have in
leveraging our brand reputation, reseller network and end use
customer base for our infant protection and wander prevention
systems to gain inroads in the emerging market for asset/staff
location and identification systems; the rate and extent of the
U.S. healthcare industry�s adoption of RFID asset/staff location
and identification systems; the relative degree of market
acceptance of our zonal, or cell ID, active RFID systems compared
to competing technologies, such as lower power Ultra Wide
Band-based location technologies; uncertainty as to whether we will
be able to increase our sales of infant protection and wander
prevention systems outside of North America; our reliance on
third-party dealers to successfully market and sell our products;
uncertainty as to whether a market for our VeriMed system will
develop and whether we will be able to generate more than a nominal
level of revenue from the sale of these systems; and market
acceptance of our VeriMed system, which will depend in large part
on the future availability of insurance reimbursement for the
VeriMed system microchip implant procedure from government and
private insurers, and the timing of such reimbursement, if it, in
fact, occurs. Additional information about these and other factors
that could affect the Company�s business is set forth in the
Company�s various filings with the Securities and Exchange
Commission, including those set forth in the Company�s 10-K filed
on April�2, 2007, under the caption �Risk Factors.� The Company
undertakes no obligation to update or release any revisions to
these forward-looking statements to reflect events or circumstances
after the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024